MARKET

OVID

OVID

Ovid Therapeutics Inc
NASDAQ
1.620
+0.040
+2.53%
Closed 19:21 12/04 EST
OPEN
1.550
PREV CLOSE
1.580
HIGH
1.670
LOW
1.550
VOLUME
1.48M
TURNOVER
0
52 WEEK HIGH
2.010
52 WEEK LOW
0.2425
MARKET CAP
115.36M
P/E (TTM)
-3.1684
1D
5D
1M
3M
1Y
5Y
1D
Ovid Therapeutics Names Petra Kaufmann Chief Medical Officer
NASDAQ · 2d ago
*Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
Dow Jones · 2d ago
Ovid Therapeutics Names Dr. Petra Kaufmann as Chief Medical Officer
Reuters · 2d ago
OVID THERAPEUTICS APPOINTS DR. PETRA KAUFMANN AS CHIEF MEDICAL OFFICER
Reuters · 2d ago
Press Release: Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
Dow Jones · 2d ago
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
Barchart · 3d ago
Weekly Report: what happened at OVID last week (1124-1128)?
Weekly Report · 4d ago
Ovid Therapeutics Price Target Raised to $2.00/Share From $1.50 by HC Wainwright & Co.
Dow Jones · 11/24 11:52
More
About OVID
Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).

Webull offers Ovid Therapeutics Inc stock information, including NASDAQ: OVID real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OVID stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OVID stock methods without spending real money on the virtual paper trading platform.